Mallinckrodt Plc Ordinary Share (MNK) 84.51 $MNK
Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:05PM CDT
Mallinckrodt plc (MNK) announced encouraging results from a phase III efficacy study on its pain candidate, MNK-155.
Mallinckrodt Pharmaceuticals Presents 11 Posters with Data on Investigational Opioid, MNK-155, and XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended Release Tablets (CII) at PAINWeek 2014
Business Wire - Fri Sep 05, 8:00AM CDT
Mallinckrodt (NYSE: MNK) presented 11 posters with data on its investigational opioid, MNK-155, an extended-release oral formulation of hydrocodone and acetaminophen, and recently FDA-approved XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), at PAINWeek, September 2-6 in Las Vegas, Nevada. The studies examined the compound's efficacy, safety, abuse-related characteristics and release/delivery profiles with immediate- and extended-release components.
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.
Today's Momo Momentum Stock To Watch: Mallinckrodt (MNK)
at The Street - Thu Sep 04, 8:50AM CDT
Trade-Ideas LLC identified Mallinckrodt (MNK) as a momo momentum candidate
Tetraphase Pharmaceuticals (TTPH) in Focus: Stock Gains 14.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:46AM CDT
Tetraphase Pharmaceuticals (TTPH) was a big mover last session, with shares rising nearly 15% on the day.
10 Stocks Billionaire John Paulson Loves in 2014
at The Street - Thu Sep 04, 8:33AM CDT
Here's a look at 10 stocks that Paulson & Co. bought in the most recently reported quarter.
Mallinckrodt Pharmaceutical's MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination, Shows Efficacy in Phase 3 Acute Pain Trial
Business Wire - Thu Sep 04, 8:00AM CDT
Mallinckrodt (NYSE: MNK) today reported that a Phase 3 efficacy trial of investigational MNK-155 met the study's primary endpoint of improved pain scores vs. placebo over the first 48 hours following bunionectomy (p<0.001). This difference in pain scores was statistically significant in favor of MNK-155. The data is being presented at PAINWeek 2014, a national conference on pain for frontline practitioners, held in Las Vegas, Nevada September 2-6, 2014.
Merck KGaA in Deal with S-TARget, Allergy Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:50PM CDT
Merck KGaA's (MKGAF) Allergopharma, strikes deal with S-TARget therapeutics for developing a new generation of therapies for allergies using S-TIR technology.
Novo Nordisk Drops Anti-Inflammatory R&D Activities - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:20PM CDT
Novo Nordisk (NVO) intends to ramp up its efforts to strengthen its core business area - diabetes prevention and treatment, obesity and diabetes complications.
Stocks End Mixed; Mallinckrodt Clears Buy Point
at Investor's Business Daily - Wed Sep 03, 4:03PM CDT
Stocks ended mixed Wednesday, with the Dow Jones industrial average edging higher and the Nasdaq erasing all of the previous day's gains amid a sell-off in Apple (AAPL) . The Dow edged up 0.1% but the Nasdaq fell 0.6% and the S&P 500 slipped 0.1%....
Drug M&A Boom Driven By Long-Term Trends: PwC
at Investor's Business Daily - Wed Sep 03, 3:22PM CDT
If you've been feeling like drugmaker mergers and acquisitions have been busting out all over the place this year, professional-services firm PricewaterhouseCoopers has the numbers to back you up. In its second-quarter report on the subject, released...
RXi Pharmaceuticals (RXII) Jumps: Stock Moves 11.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 8:46AM CDT
RXi Pharmaceuticals (RXII) was a big mover last session, with shares rising over 11% on the day.
Mallinckrodt Pharmaceuticals Releases Human Abuse Liability (HAL) Data for Investigational MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination
Business Wire - Wed Sep 03, 8:02AM CDT
Mallinckrodt (NYSE: MNK) today reported data from a Human Abuse Liability (HAL) study in which both intact and crushed MNK-155 showed lower subjective abuse-related effects than an immediate-release hydrocodone bitartrate/acetaminophen formulation (a generic form of Vicodin(R)). The data will be presented at PAINWeek 2014, a national conference on pain for frontline practitioners, in Las Vegas, Nevada September 2-6, 2014.
Mallinckrodt Pharmaceuticals to Hold Investor Briefing October 14, 2014, in New York
Business Wire - Tue Sep 02, 3:10PM CDT
Mallinckrodt plc. (NYSE: MNK), a leading global specialty pharmaceutical company, will hold an investor briefing on Tuesday, October 14, 2014, in New York City. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will present along with members of Mallinckrodt's senior management team. The presentation will include announcement of the company's fiscal year 2015 financial guidance.
Novo Nordisk's Ryzodeg Now in Mexico for Type II Diabetes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 2:00PM CDT
Novo Nordisk (NVO) has launched its type II diabetes treatment, Ryzodeg, in Mexico. This makes Mexico the first country where Ryzodeg is commercially available.
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Upcoming Conferences, Market Activity, Drug Approval, and Earnings Release - Research Reports on Mallinckrodt, Vertex Pharmaceuticals, Kite, Bristol-Myers Squibb and Arrowhead
PR Newswire - Fri Aug 29, 7:40AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt plc (NYSE: MNK), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Kite Pharma, Inc. (NASDAQ: KITE), Bristol-Myers Squibb Company (NYSE: BMY) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6071-100free.
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Actavis has filed an ANDA with the FDA seeking marketing approval for its generic version of UCB's Neupro. In response, UCB filed a lawsuit against Actavis.
Mallinckrodt Pharmaceuticals to Present Data for Investigational and Approved Extended-Release Opioid Combination Medicines at PAINWeek
Business Wire - Thu Aug 28, 8:00AM CDT
Mallinckrodt (NYSE: MNK) today announced that clinical data for its investigational opioid, MNK-155 (hydrocodone bitartrate and acetaminophen) and approved opioid combination product XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) will be presented at PAINWeek 2014, a national conference on pain for frontline practitioners, September 2-6, in Las Vegas, Nevada.
Mallinckrodt Nears Buy Point As Sales, Earnings Rise
at Investor's Business Daily - Wed Aug 27, 5:12PM CDT
Drugmaker Mallinckrodt, bulked up by buying Questcor Pharmaceuticals in August and buoyed by its addition to the S&P 500 index, has in the past several months become much more interesting than it used to be. Mallinckrodt's (MNK) earnings fell in 2010...
Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:05PM CDT
Mallinckrodt plc (MNK) announced encouraging results from a phase III efficacy study on its pain candidate, MNK-155.
Mallinckrodt Pharmaceuticals Presents 11 Posters with Data on Investigational Opioid, MNK-155, and XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended Release Tablets (CII) at PAINWeek 2014
Business Wire - Fri Sep 05, 8:00AM CDT
Mallinckrodt (NYSE: MNK) presented 11 posters with data on its investigational opioid, MNK-155, an extended-release oral formulation of hydrocodone and acetaminophen, and recently FDA-approved XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), at PAINWeek, September 2-6 in Las Vegas, Nevada. The studies examined the compound's efficacy, safety, abuse-related characteristics and release/delivery profiles with immediate- and extended-release components.
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.
Today's Momo Momentum Stock To Watch: Mallinckrodt (MNK)
at The Street - Thu Sep 04, 8:50AM CDT
Trade-Ideas LLC identified Mallinckrodt (MNK) as a momo momentum candidate
Tetraphase Pharmaceuticals (TTPH) in Focus: Stock Gains 14.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:46AM CDT
Tetraphase Pharmaceuticals (TTPH) was a big mover last session, with shares rising nearly 15% on the day.
10 Stocks Billionaire John Paulson Loves in 2014
at The Street - Thu Sep 04, 8:33AM CDT
Here's a look at 10 stocks that Paulson & Co. bought in the most recently reported quarter.
Mallinckrodt Pharmaceutical's MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination, Shows Efficacy in Phase 3 Acute Pain Trial
Business Wire - Thu Sep 04, 8:00AM CDT
Mallinckrodt (NYSE: MNK) today reported that a Phase 3 efficacy trial of investigational MNK-155 met the study's primary endpoint of improved pain scores vs. placebo over the first 48 hours following bunionectomy (p<0.001). This difference in pain scores was statistically significant in favor of MNK-155. The data is being presented at PAINWeek 2014, a national conference on pain for frontline practitioners, held in Las Vegas, Nevada September 2-6, 2014.
Merck KGaA in Deal with S-TARget, Allergy Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:50PM CDT
Merck KGaA's (MKGAF) Allergopharma, strikes deal with S-TARget therapeutics for developing a new generation of therapies for allergies using S-TIR technology.
Novo Nordisk Drops Anti-Inflammatory R&D Activities - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:20PM CDT
Novo Nordisk (NVO) intends to ramp up its efforts to strengthen its core business area - diabetes prevention and treatment, obesity and diabetes complications.
Stocks End Mixed; Mallinckrodt Clears Buy Point
at Investor's Business Daily - Wed Sep 03, 4:03PM CDT
Stocks ended mixed Wednesday, with the Dow Jones industrial average edging higher and the Nasdaq erasing all of the previous day's gains amid a sell-off in Apple (AAPL) . The Dow edged up 0.1% but the Nasdaq fell 0.6% and the S&P 500 slipped 0.1%....
Drug M&A Boom Driven By Long-Term Trends: PwC
at Investor's Business Daily - Wed Sep 03, 3:22PM CDT
If you've been feeling like drugmaker mergers and acquisitions have been busting out all over the place this year, professional-services firm PricewaterhouseCoopers has the numbers to back you up. In its second-quarter report on the subject, released...
RXi Pharmaceuticals (RXII) Jumps: Stock Moves 11.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 8:46AM CDT
RXi Pharmaceuticals (RXII) was a big mover last session, with shares rising over 11% on the day.
Mallinckrodt Pharmaceuticals Releases Human Abuse Liability (HAL) Data for Investigational MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination
Business Wire - Wed Sep 03, 8:02AM CDT
Mallinckrodt (NYSE: MNK) today reported data from a Human Abuse Liability (HAL) study in which both intact and crushed MNK-155 showed lower subjective abuse-related effects than an immediate-release hydrocodone bitartrate/acetaminophen formulation (a generic form of Vicodin(R)). The data will be presented at PAINWeek 2014, a national conference on pain for frontline practitioners, in Las Vegas, Nevada September 2-6, 2014.
Mallinckrodt Pharmaceuticals to Hold Investor Briefing October 14, 2014, in New York
Business Wire - Tue Sep 02, 3:10PM CDT
Mallinckrodt plc. (NYSE: MNK), a leading global specialty pharmaceutical company, will hold an investor briefing on Tuesday, October 14, 2014, in New York City. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will present along with members of Mallinckrodt's senior management team. The presentation will include announcement of the company's fiscal year 2015 financial guidance.
Novo Nordisk's Ryzodeg Now in Mexico for Type II Diabetes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 2:00PM CDT
Novo Nordisk (NVO) has launched its type II diabetes treatment, Ryzodeg, in Mexico. This makes Mexico the first country where Ryzodeg is commercially available.
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Upcoming Conferences, Market Activity, Drug Approval, and Earnings Release - Research Reports on Mallinckrodt, Vertex Pharmaceuticals, Kite, Bristol-Myers Squibb and Arrowhead
PR Newswire - Fri Aug 29, 7:40AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt plc (NYSE: MNK), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Kite Pharma, Inc. (NASDAQ: KITE), Bristol-Myers Squibb Company (NYSE: BMY) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6071-100free.
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Actavis has filed an ANDA with the FDA seeking marketing approval for its generic version of UCB's Neupro. In response, UCB filed a lawsuit against Actavis.
Mallinckrodt Pharmaceuticals to Present Data for Investigational and Approved Extended-Release Opioid Combination Medicines at PAINWeek
Business Wire - Thu Aug 28, 8:00AM CDT
Mallinckrodt (NYSE: MNK) today announced that clinical data for its investigational opioid, MNK-155 (hydrocodone bitartrate and acetaminophen) and approved opioid combination product XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) will be presented at PAINWeek 2014, a national conference on pain for frontline practitioners, September 2-6, in Las Vegas, Nevada.
Mallinckrodt Nears Buy Point As Sales, Earnings Rise
at Investor's Business Daily - Wed Aug 27, 5:12PM CDT
Drugmaker Mallinckrodt, bulked up by buying Questcor Pharmaceuticals in August and buoyed by its addition to the S&P 500 index, has in the past several months become much more interesting than it used to be. Mallinckrodt's (MNK) earnings fell in 2010...
